LSD May Enhance Brain Rewiring and Alleviate Anxiety Tumegy/Science Photo Library/Getty Images
Two significant trials examining the potential of the hallucinogen LSD to alleviate anxiety are set to conclude in 2026. Early-stage trials have shown promising results, potentially allowing the treatment to be available in the United States by 2027.
Generalized anxiety disorder is prevalent, causing intense anxiety about various issues. Traditional treatments often include antidepressants and talk therapy, yet approximately half of patients do not respond adequately.
Other psychedelics, like psilocybin and MDMA, are already being utilized in certain nations, including Australia and Switzerland, to treat severe depression and PTSD. LSD is gaining attention in mental health studies, primarily because it has been shown to induce deep emotional experiences and may enhance the brain’s capacity to form new neural connections.
A pivotal trial in 2025 demonstrated that a single high dose of LSD significantly reduced moderate to severe anxiety for a duration of at least three months.
Currently, two late-stage trials are ongoing, with results expected in 2026. Each trial involves about 200 participants with moderate to severe anxiety who will receive either 100 micrograms of LSD or a placebo. Their anxiety levels will be monitored over three months post-administration.
In the subsequent 10-month phase, all participants, including those initially on a placebo, will have the opportunity to take LSD if they report their anxiety reaching a predefined threshold on a standardized scale. This design aims to assess the duration of effects following a single dose. Dan Carlin, affiliated with New York biotech firm MindMed, has been involved in both the 2025 trial and the current studies.
The primary distinction between the two studies is that, in the second trial, an additional group will receive 50 micrograms of LSD. The 2025 trial indicated this dosage could induce hallucinations but didn’t effectively diminish anxiety compared to the placebo, thereby addressing a common challenge in psychedelic research—participants often struggle to identify if they received the active drug.
Participants in this third group will be aware they received LSD but will remain uncertain if the dosage is sufficient to alleviate anxiety, as noted by Sandeep Nayak of Johns Hopkins Bayview Medical Center, who is not part of these trials.
If the results of both trials are favorable, the FDA could approve LSD for anxiety treatment in the United States by 2027, potentially leading to approval in Europe and other regions.
“If the upcoming trial confirms results similar to the previous ones from 2025, that should satisfy the FDA,” said Boris Heifetz of Stanford University.
A meaningful impact on patients’ lives is typically defined as a 3 to 5-point difference on the anxiety scale between placebo and LSD groups, as noted by Nayak. The 2025 trial showed a difference of approximately five points, indicating a strong possibility the next trial will meet this threshold. However, any therapeutic benefits must be weighed against the duration of effects and potential side effects.
For instance, temporary psychological distress during treatment might be acceptable to the FDA, unlike long-lasting distress, Nayak stated. Notably, long-term distress was not observed in the 2025 trial.
Even with potential approval, Nayak emphasizes it may take several years for LSD to become widely accessible for anxiety disorders, and it would likely be a last-resort treatment after conventional therapies fail. This is primarily due to the logistical challenges, such as the need for clinicians to supervise patients during psychedelic experiences.
Topics:
Source: www.newscientist.com
